Species Reactivity:
Negative Species:
|
Applications:
Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.
|
General references
*Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis. 2001 Nov 15;184(10):1310-4. [Abstract] [Full Text]
*Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med. 2004 Mar 15;169(6):696-702.
[Abstract] [Full Text]
*Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens. 2007 Oct;70(4):283-93. [Abstract]
*Harjacek M, Margetiĉ T, Kerhin-Brkljaciĉ V, Martinez N, Grubiĉ Z: HLA-B*27/HLA-B*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. Clin Exp Rheumatol. 2008 May-Jun;26(3):498-504. [Abstract]
Product Specific References
*Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999 Oct;5(10):2766-72. [Abstract] [Full Text]
*Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol. 2006 Dec;18(12):1707-18. [Abstract] [Full Text]
*Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol Cell Proteomics. 2005 Dec;4(12):1888-97.
[Abstract] [Full Text]
*Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. Immunol. 2008 Oct 15;181(8):5442-50. [Abstract] [Full Text]
*Trapani JA, Vaughan HA, Tait BD, McKenzie IF: Immunoradiometric assay for the rapid detection of HLA-B27. Immunol Cell Biol. 1988 Jan;66 ( Pt 3):215-9. [Abstract]
*de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002 Jun;128(3):525-31. [Abstract] [Full Text]
*Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2361-4. [Abstract]
*Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15;61(18):6868-75. [Abstract] [Full Text]
*Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11. [Abstract]
|